Key Points
- CEO Pardeep Nijhawan disclosed multiple insider purchases (10,000 shares on Mar 5 at $3.90 plus prior buys on Mar 3, Feb 27 and Feb 26), totaling 70,571 shares, bringing his direct holding to 402,702 shares (≈$1.57M) — a 2.55% increase in his position.
- EDSA shares jumped $2.91 to $6.52 on high volume (31.86M vs. average 10.13M), trading between a 52-week low of $0.72 and high of $7.43, with a market cap of about $54.4M and a negative P/E of -5.67.
- Edesa is a clinical‑stage biotech developing self‑amplifying RNA vaccines (including an intranasal COVID‑19 candidate); analyst coverage is mixed with a consensus "Hold" and average target of $5.00, while Weiss Ratings recently reiterated a "sell (e+)" stance.
Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan bought 10,000 shares of the firm's stock in a transaction dated Thursday, March 5th. The shares were purchased at an average price of $3.90 per share, with a total value of $39,000.00. Following the acquisition, the chief executive officer directly owned 402,702 shares in the company, valued at approximately $1,570,537.80. This trade represents a 2.55% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Pardeep Nijhawan also recently made the following trade(s):
- On Tuesday, March 3rd, Pardeep Nijhawan bought 10,000 shares of Edesa Biotech stock. The stock was acquired at an average cost of $3.63 per share, for a total transaction of $36,300.00.
- On Friday, February 27th, Pardeep Nijhawan acquired 30,000 shares of Edesa Biotech stock. The stock was bought at an average cost of $2.22 per share, for a total transaction of $66,600.00.
- On Thursday, February 26th, Pardeep Nijhawan purchased 20,571 shares of Edesa Biotech stock. The shares were bought at an average cost of $1.58 per share, for a total transaction of $32,502.18.
Edesa Biotech Stock Performance
Shares of EDSA stock traded up $2.91 on Friday, hitting $6.52. The stock had a trading volume of 31,861,352 shares, compared to its average volume of 10,134,933. Edesa Biotech, Inc. has a 52-week low of $0.72 and a 52-week high of $7.43. The firm has a market capitalization of $54.44 million, a price-to-earnings ratio of -5.67 and a beta of 0.05. The stock's 50 day moving average is $1.60 and its 200-day moving average is $1.94.
Edesa Biotech (NASDAQ:EDSA - Get Free Report) last posted its quarterly earnings data on Friday, February 13th. The company reported ($0.28) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.28). The firm had revenue of $0.10 million during the quarter. Equities analysts expect that Edesa Biotech, Inc. will post -1.75 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Edesa Biotech in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $5.00.
View Our Latest Stock Report on EDSA
Institutional Investors Weigh In On Edesa Biotech
Several institutional investors and hedge funds have recently bought and sold shares of the business. DRW Securities LLC bought a new position in Edesa Biotech in the fourth quarter worth about $191,000. Diadema Partners LP acquired a new stake in shares of Edesa Biotech during the 4th quarter worth approximately $77,000. State Street Corp bought a new stake in shares of Edesa Biotech in the 4th quarter worth approximately $27,000. Finally, Susquehanna International Group LLP acquired a new position in Edesa Biotech during the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 5.50% of the company's stock.
About Edesa Biotech
(
Get Free Report)
Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa's approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.
Among Edesa's pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
